株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アルツハイマー病関連の認知症:パイプライン製品の分析

Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 265422
出版日 ページ情報 英文 73 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.77円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
アルツハイマー病関連の認知症:パイプライン製品の分析 Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016
出版日: 2016年10月26日 ページ情報: 英文 73 Pages
概要

アルツハイマー病は、記憶・思考・行動の障害を引き起こす認知症の一種です。鬱病、社会的ひきこもり、気分のむら、短気、攻撃性、抑制の低下などの症状が見られます。危険因子は、年齢、家族歴、軽度認知障害(MCI)です。治療には、コリンエステラーゼ阻害薬、健康的な生活スタイルなどが含まれます。

当レポートでは、アルツハイマー病関連の認知症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アルツハイマー病関連の認知症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

アルツハイマー病関連の認知症:企業で開発中の治療薬

アルツハイマー病関連の認知症:大学/機関で研究中の治療薬

アルツハイマー病関連の認知症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

アルツハイマー病関連の認知症:企業で開発中の製品

アルツハイマー病関連の認知症:大学/機関で研究中の製品

アルツハイマー病関連の認知症の治療薬開発に従事している企業

  • Adamas Pharmaceuticals, Inc.
  • AgeneBio Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Boehringer Ingelheim GmbH
  • Chase Pharmaceuticals Corporation
  • エーザイ
  • FORUM Pharmaceuticals Inc.
  • H. Lundbeck A/S
  • MediPost Co., Ltd.
  • Neurodyn Inc.

アルツハイマー病関連の認知症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

アルツハイマー病関連の認知症:最近のパイプライン動向

アルツハイマー病関連の認知症:休止中のプロジェクト

アルツハイマー病関連の認知症:開発が中止された製品

アルツハイマー病関連の認知症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8589IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides an overview of the Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline landscape.

Dementia is a general term for loss of memory and other mental abilities severe enough to interfere with daily life. Alzheimer's is a type of dementia. Symptoms include depression, social withdrawal, mood swings, irritability and aggressiveness and loss of inhibitions. Risk factors include age, family history and mild cognitive impairment. Treatment includes cholinesterase inhibitors and healthy life style.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dementia Associated With Alzheimer's Disease - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia Associated With Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Unknown stages are 6, 2 and 1 respectively for Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively for Dementia Associated With Alzheimer's Disease.

Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia Associated With Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Dementia Associated With Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Dementia Associated With Alzheimer's Disease (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Dementia Associated With Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Dementia Associated With Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Dementia Associated With Alzheimer's Disease Overview
  • Therapeutics Development
    • Pipeline Products for Dementia Associated With Alzheimer's Disease - Overview
    • Pipeline Products for Dementia Associated With Alzheimer's Disease - Comparative Analysis
  • Dementia Associated With Alzheimer's Disease - Therapeutics under Development by Companies
  • Dementia Associated With Alzheimer's Disease - Therapeutics under Investigation by Universities/Institutes
  • Dementia Associated With Alzheimer's Disease - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Dementia Associated With Alzheimer's Disease - Products under Development by Companies
  • Dementia Associated With Alzheimer's Disease - Products under Investigation by Universities/Institutes
  • Dementia Associated With Alzheimer's Disease - Companies Involved in Therapeutics Development
    • Adamas Pharmaceuticals, Inc.
    • AgeneBio Inc.
    • Amarantus Bioscience Holdings, Inc.
    • Boehringer Ingelheim GmbH
    • Chase Pharmaceuticals Corporation
    • Eisai Co., Ltd.
    • H. Lundbeck A/S
    • MediPost Co., Ltd.
  • Dementia Associated With Alzheimer's Disease - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (donepezil hydrochloride + memantine hydrochloride ER) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (donepezil hydrochloride + solifenacin succinate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BI-409306 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • E-2609 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eltoprazine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gln-1062 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levetiracetam - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LUAF-20513 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Neurostem - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • salicylamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-070 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Dementia Associated With Alzheimer's Disease - Dormant Projects
  • Dementia Associated With Alzheimer's Disease - Discontinued Products
  • Dementia Associated With Alzheimer's Disease - Product Development Milestones
    • Featured News & Press Releases
      • Aug 31, 2016: Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC Patent Litigation
      • Jul 27, 2016: Chase Pharmaceuticals Presents Phase 2 Results for CPC-201 at 2016 Alzheimer's Association International Conference
      • Feb 17, 2016: AgeneBio to Present at Neuroscience BioPartnering & Investment Forum
      • Dec 15, 2015: AgeneBio Launches New HOPE4MCI Phase 3 Clinical Trial Website
      • Dec 08, 2015: Amarantus Announces Positive Phase 2 Data for Eltoprazine in Alzheimer's Aggression
      • Nov 24, 2015: AgeneBio to Present at Future of Innovation in Medicine Conference
      • Oct 22, 2015: AgeneBio to Present at 8th Annual Clinical Trials on Alzheimer's Disease
      • Sep 15, 2015: NIH Awards $7.5 Million Grant for AgeneBio HOPE4MCI Phase 3 Clinical Trial to Delay the Onset of Alzheimer's Dementia
      • Mar 11, 2015: AgeneBio Announces Publication of Phase 2 Clinical Trial Results for New Approach to Delaying the Onset of Alzheimer's Dementia
      • Jan 28, 2015: AgeneBio Receives Grant from Alzheimer's Drug Discovery Foundation for New Approach to Delaying the Onset of Alzheimer's Dementia
      • May 20, 2014: Adamas Pharmaceuticals Receives $25 Million Milestone Payment From Forest Laboratories
      • May 15, 2012: Adamas Announces Successful End-Of-Phase II Meeting With FDA For Arimenda
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016
  • Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by AgeneBio Inc., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Chase Pharmaceuticals Corporation, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by Eisai Co., Ltd., H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by H. Lundbeck A/S, H2 2016
  • Dementia Associated With Alzheimer's Disease - Pipeline by MediPost Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Dementia Associated With Alzheimer's Disease - Dormant Projects, H2 2016
  • Dementia Associated With Alzheimer's Disease - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Dementia Associated With Alzheimer's Disease, H2 2016
  • Number of Products under Development for Dementia Associated With Alzheimer's Disease - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top